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Fabry Disease (FD) is characterized by globotriaosylceramide-3 (Gb3) accumulation in sev-
eral tissues and a small fibre neuropathy (SFN), however the underlying mechanisms are
poorly known. This study aimed to: 1) ascertain the presence of Gb3 deposits in skin sam-
ples, by an immunofluorescence method collected from FD patients with classical GLA
mutations or late-onset FD variants or GLA polymorphisms; 2) correlate skin GB3 deposits
with skin innervation.
Methods
we studied 52 genetically-defined FD patients (32 with classical GLA mutations and 20 with
late-onset variants or GLA polymorphisms), 15 patients with SFN associated with a specific
cause and 22 healthy controls. Subjects underwent skin biopsy to evaluate Gb3 deposits
and epi-dermal innervation.
Results
Skin Gb3 deposits were found in all FD patients with classical GLA mutations but never in
FD patients with late-onset variants or GLA polymorphisms or in patients with SFN and
healthy controls. Abnormal deposits were found inside different skin structures but never
inside axons. FD patients with GB3 deposits showed lower skin innervation than FD patients
with late-onset variants or polymorphisms.
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Conclusions
1) Skin Gb3 deposits are specific to FD patients with classical GLA mutations; 2) Gb3
deposits were associated with lower skin innervation but they were not found inside axons,
suggesting an indirect damage on peripheral small fibre innervation.
Introduction
Fabry Disease (FD) is a rare x-linked disorder[1] characterized by an abnormal function of the
lysosomal enzyme alpha-galactosidase A (GLA)[2,3], involved in the cleavage of galactose
residuals of globotriaosylceramide-3 (Gb3)[4]. As a consequence, Gb3 starts to accumulate
within lysosomes of several tissues involving blood vessels, kidneys, nervous system and heart,
as well as dermal fibroblasts[5–8], accounting for FD’s clinical features[9,10] mainly including
small fibre neuropathy (SFN)[11], stroke, and renal and cardiac dysfunctions[12]. SFN is
mainly responsible for paraesthesias of extremities, hypohydrosis, abdominal pain and diar-
rhoea[5,11,12] often beginning in childhood with progressive severity throughout life. The
available enzyme replacement therapy (ERT) started early before the appearance of organ fail-
ure may decrease the pathological impact of this disorder[5].
The possibility to disclose skin Gb3 deposits is interesting because skin is an easily accessi-
ble tissue. Skin Gb3 deposits have been demonstrated by using complex techniques such as
electron microscopy[13] but they can also be detected by more simple and rapid techniques
such as light microscopy[14,15]. However, by using this latter technique skin Gb3 deposits
were not found in all analysed patients[15,16], preventing the use of this approach for diagnos-
tic purposes. The reason of the absence of Gb3 deposits in the skin samples of few FD patients
is unknown, although a possible correlation with plasma lyso-GL-3 levels was suggested[15].
However, skin Gb3 deposits in classical or late-onset GLA mutations or in healthy controls or
patients with SFN of different origin to evaluate their specificity in FD have not been previ-
ously studied. In addition, SFN underlying mechanisms in FD are poorly known since con-
trasting findings were reported in animals[17] and humans[18–20].
Specific aims of this study were: 1) to ascertain the presence of Gb3 deposits in skin samples
collected from FD patients with classical GLA mutations or late-onset FD variants or GLA
polymorphisms by an immunofluorescence method; and 2) to ascertain the correlation of skin
Gb3 deposits with the skin innervation.
Materials and methods
We studied 52 genetically-defined FD patients including 14 males and 38 females (36±15 vs
45±14 years; p = 0.05) who belong to 26 different families (Tables 1 and 2). Patients were re-
cruited in different FD tertiary centres and evaluated at IRCCS Institute of Neurological Sciences
of Bologna. They included 32 patients with classical GLA mutations; 17 patients with late-onset
FD variants and 3 patients with GLA polymorphisms, subsequently named as non-classical
mutations group (Table 2). To test the specificity of skin Gb3 deposits in FD patients, Gb3 were
also searched in 15 patients with SFN associated with specific causes (i.e. 4 patients with diabetes,
3 with Sjogren disease, 2 with hepatitis C, 3 with Parkinson’s disease and 3 with amyotrophic
lateral sclerosis) and 22 healthy controls. SFN patients and controls were sex- (5M:10F and
10M:12F respectively) and age-matched (49±8 and 46±18) compared to FD patients (Table 1).
The procedures used were approved by the Human Ethics Committee of Policlinico San-
t’Orsola-Malpighi (Bologna) and followed the Helsinki Declaration regarding international
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analysis, decision to publish, or preparation of the
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Table 1. Clinical and laboratory findings in patients with Fabry disease.
FD pt Sex Age Pain Skin Gb3 Skin innervation αGAL activity ERT
M:F years % Leg (EFNs/mm)^ Thigh (EFNs/mm)§ % months
1 F 43 4 80 8,8 12 131 6
2 M 13 absent 100 7,3 11 100 40
3 M 16 absent 100 4 15,5 100 62
4 F 21 2 63 16,4 na 134 -
5 F 32 absent 75 4,1 4,4 100 -
6 M 36 8 100 1,5 3,3 130 3
7 F 59 absent 80 4,1 4,7 140 -
8 M 17 6 100 7,8 11,6 100 -
9 F 19 3 50 8,9 8,3 33,5 -
10 F 46 7 50 5,7 12 14 -
11 M 37 4 100 7,8 15,4 na -
12 F 46 8 50 7,8 15,4 55 -
13 F 27 3 100 9,6 18 84 156
14 F 33 absent 100 3,9 19,9 33 -
15 F 43 4 50 7,2 9,2 54 -
16 F 42 5 50 3 5,5 20,5 -
17 F 55 absent 50 5,6 na na -
18 M 32 8 100 0 na 96,2 96
19 M 49 8 100 1 1,75 96 84
20 F 62 5 50 6,5 na 59,2 -
21 M 32 6 100 2,4 0,6 95,5 39
22 F 51 6 75 9,1 10,5 230 52
23 F 27 absent 75 6,7 na 49,8 -
24 M* 48 absent 100 5 8 82 84
25 F 52 absent 75 6 na 200 60
26 M 34 4 100 4,2 8 96,8 84
27 F 57 absent 75 4,8 9 300 60
28 F 51 2 100 2,5 4,4 na 1
29 M 25 4 100 5 9,2 96,1 2
30 M 49 3 100 0 5 42,3 7
31 F 41 absent 25 8 na 180 -
32 F 49 2 75 10,6 14,2 na -
33 F 63 absent 0 10,9 14,7 31,3 57
34 F 28 7 0 10,9 13,5 62,1 -
35 F 31 absent 0 8,75 12,6 47,3 -
36 F 36 absent 0 6,9 10,5 67,2 -
37 F 28 absent 0 14,6 17,8 108 66
38 F 79 6 0 6,1 6,1 na -
39 M* 65 3 0 6,6 6,9 na 7
40 M 48 absent 0 5,5 9,8 na -
41 F 46 3 0 6,1 4,8 na -
42 F 41 2 0 8,2 18,4 na -
43 F 30 absent 0 9,9 12,1 na -
44 F 72 10 0 1,5 14,8 na -
45 F 58 3 0 12,6 16 20 -
46 F 33 2 0 17,3 21 na -
(Continued )
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clinical research involving human beings. All subjects gave their written informed consent to
the study.
Alpha-GAL activity
Alpha-GAL activity was tested in 39 patients; the remaining 13 patients performed only the
genetic analysis because alpha-GAL activity was thought to be a non-diagnostic priority since
patients belong to a family with an FD mutation. In addition, this test was performed in several
laboratories with different normative values. To obtain a uniform value among different
Table 1. (Continued)
FD pt Sex Age Pain Skin Gb3 Skin innervation αGAL activity ERT
M:F years % Leg (EFNs/mm)^ Thigh (EFNs/mm)§ % months
47 F* 58 absent 0 6 12,7 na 11
48 F 42 3 0 11,3 23,7 145 -
49 F 60 absent 0 5,9 4,8 126 -
50 F 52 6 0 5,1 14,8 na -
51 F 40 absent 0 16,8 25,2 119 -
52 F 43 absent 0 8,2 11,3 26 -
mean±SD 14:38 42±15 5±2 49±43 7±4 11±6 76±71 49±41
Rows 1-32: patients with classical GLA mutations and positive skin Gb3 deposits; Rows 33-52: patients with non-classical GLA mutations and negative skin
Gb3 deposits; ERT = enzyme replacement therapy; n.a. = not available; ENFs = number of unmyelinated fibres per linear millimeter of epidermis
* = patients with renal failure
^ = age- and sex-adjusted normative values were taken from Provitera et al., 2016 [32]
§ = laboratory normative values are 24±5 EFNs/mm; cut-off of 12 EFNs/mm for old people (>60 years old) and 27±6 EFNs/mm; cut-off of 14 EFNs/mm for
youngest people (<60 years old). We have to use our normative values since no published data are available for the thigh immunofluorescent method.
https://doi.org/10.1371/journal.pone.0180581.t001
Table 2. Genetic analysis in patients with Fabry disease.
Skin Gb3 deposits No skin Gb3 deposits
GLA Mutations Effect Type Pt Family GLA Mutations Effect Type Pt Families
c.680G>C (R227Q) missense classical 3 1 c.644A>G (N215S) missense cardiac variant[25] 9 4
c.837G>C (Q279H) missense classical 3 1 c.1061T>A (I354K) missense late onset variant[33] 5 1
c.861G>A (W287X) deletion classical 3 1 c.427G>A (A143T) missense Polymorphism[34] 2 1
c.514T>C (C172R) missense classical 2 1 c.335G>A (R112H) missense late onset variant[35] 1 1
c.1A>G (M1V) missense classical 2 1 c.901C>G (R301G) missense cardiac variant[24] 1 1
c.2T>C (M1T) missense classical 2 1 c.937G>T (D313Y) missense Polymorphism[36] 1 1
c.1244T>C (PL415P) missense classical 1 1 c.1078G>A (G360S) missense late onset variant[37] 1 1
c.611G>T missense classical 1 1
c.835C>A (Q279K) missense classical 1 1
c.1073-1074 insA deletion classical 4 1
c.618_627 delinsA deletion classical 3 1
c.1163-1165 del TCC missense classical 3 1
c.548-3_553del9 deletion classical 1 1
c.1006delG deletion classical 1 1
c.1277-1278del AA deletion classical 1 1
c.861-5 C>T (g.9273C>T) deletion classical 1 1
GLA = alpha-galactosidase A; Pt = patients
https://doi.org/10.1371/journal.pone.0180581.t002
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patients, alpha-GAL activity was normalized to the lower cut-off value (i.e., 100% was the
lower cut-off value; <100% corresponds to an abnormal value and>100% to a normal value;
when alpha-GAL activity value was 0 the normalized value was 0%).
Clinical examination and laboratory tests
All patients performed a neurological examination. Pain was evaluated by means of a visual
analogue scale (VAS), scale marking the level of pain on a 100 mm, non-hatched scale which
reported at one end “no pain” and at the other “worst pain imaginable”[20]. A standard motor
(tibial nerve bilaterally) and antidromic sensory (sural nerve bilaterally) conduction studies
were performed in all patients. Kidney function was evaluated by the glomerular filtration rate
(GFR) and considered normal with GFR60 ml/min/1.73 m2[21]. Cardiomyopathy was diag-
nosed in the presence of cardiac fibrosis and left ventricular hypertrophy. Ocular involvement
was characterized by corneal changes (”cornea verticillata“) or retinal vessel tortuosity[3].
Skin biopsy
Three mm punch biopsies were taken from proximal (thigh: 15 cm above the patella) and dis-
tal (leg: 10 cm above the lateral malleolus) hairy skin sites. We were unable to take skin samples
from the thigh in 6 patients because of patient’s refusal. According to previously published
procedures[22] skin samples were immediately fixed in cold Zamboni’s fixative and stored at
4˚C overnight.
Gb3 deposits. Fifty μm sections were obtained using a freezing sliding microtome
(HM550, Thermo Scientific, Walthan, MA, USA) to evaluate Gb3 deposits. Usually 3 free-
floating sections were analysed for each skin sample. They were immunostained overnight
with a panel of primary antibodies including mouse monoclonal anti-Gb3 (1:1000, TCI chemi-
cals, Portland, Oregon, USA; cat. no. A2506), rabbit pan-neuronal marker protein gene prod-
uct 9.5 (1:1000; AbD Serotec, Raleigh, NC, USA, cat. no. 7863–0504) and rabbit polyclonal
anti-collagen IV (1:500; Novus Biologicals, Littleton, CO, USA; cat. no. NB120-6586). Sections
were then washed and secondary antibodies were added for an overnight incubation. As sec-
ondary antibodies, an anti-rabbit Alexa Fluor(R) 488 (1:400; Jackson ImmunoResearch, West
Grove, PA, USA; cat. no. 711-545-152) or mouse cyanine dye fluorophores 3.18 (1:800; Jack-
son ImmunoResearch, West Grove, PA, USA; cat. no. 715-165-150) were used. ULEX euro-
paeus (1:100; Vector Laboratories, Burlingame, CA, USA; cat. no. B-1065), a biotinylated
endothelium binding lectin, labeled with cyanine dye fluorophore 5.18 coupled with streptavi-
din (1:400; Jackson ImmunoResearch; cat. no. 016-170-084) was used to show the endothe-
lium. Sections were viewed and analysed under a Nikon confocal microscopy (Eclipse Ti A1).
Each image was collected in successive frames of 1–2 μm increments on a Z-stack plan at the
appropriate wavelengths for secondary antibodies with a x40 or x60 plan apochromat objective
and subsequently projected to obtain a triple-stained 3D digital image by a computerized sys-
tem. The microscope settings were kept the same for all cases analysed. The analysis was made
in a blinded fashion by two authors with expertise in immunoflorescent analysis (DV and IA).
Full agreement on the Gb3 staining was reached by the two analysers in all cases without any
discordance or uncertain classification (i.e. positive or negative staining in each skin sample
analysed). Gb3 staining was rated in each skin site as the percentage of skin structures showing
a positive staining at high magnification (x40).
Skin innervation. Additional 50 μm sections from the same skin sample were obtained
during the freezing sliding microtome session. Three free-floating sections were incubated
overnight with a panel of primary antibodies, including the rabbit pan-neuronal marker pro-
tein gene product 9.5 (1:1000; AbD Serotec, Raleigh, NC, USA, cat. no. 7863–0504) and mouse
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collagen IV (ColIV, 1:800, Chemicon, Temecula, CA, USA, cat. no. MAB1910) to define the
basal membrane dividing epidermis from dermis. Sections were then washed and secondary
antibodies, labeled with mouse Alexa Fluor(R) 488 (1:400; Jackson ImmunoResearch, West
Grove, PA, USA, cat. no. 715-545-150) and rabbit cyanine dye fluorophores 3.18 (1:800; Jack-
son ImmunoResearch, West Grove, PA, USA; cat. no. 711-165-152) were added for an over-
night incubation. Epidermal nerve fibre density (ENFs: number of unmyelinated fibres per
linear millimetre of epidermis) was calculated by considering a single epidermal nerve fibre
marked by PGP 9.5 crossing the dermal–epidermal junction.
Statistical analysis
We performed statistical analyses using SPSS 15.0 for Windows. Parametric tests were used as
Kolmogorov–Smirnov test showed that the variables were normally distributed. Unpaired Stu-
dent’s t test was used to compare clinical and demographic data between: 1) FD patients vs
controls or SFN patients; 2) FD subgroups (classical vs non-classical GLA mutations; males vs
females; high vs low skin Gb3 load; ERT vs without ERT). Linear correlation using Pearson
test was used to correlate skin Gb3 deposits with clinical parameters or innervation scores.
p<0.05 was considered significant.
Results
Clinical data
Neurological examination was essentially normal in FD patients except for 2 male patients
showing distal tactile sensory loss with a sock distribution. Pain was reported by 21 FD
patients, more by males (72%; mean VAS value 50±20) than by females (54%; VAS value 40
±20). Pain was more frequent in patients with classical mutations (66% vs 50%). Autonomic
symptoms were reported by 22 patients and mainly included palm and sole sweating loss (19
patients) and gastrointestinal dysmotility with nausea, bloating, abdominal cramps or diar-
rhoea (6) primarily in the group of classical mutations (53% vs 25%). Fifteen patients, mainly
those with non-classical mutations (35% vs 20%) had cardiomyopathy. Ten patients (7 with
classical and 3 with non-classical mutations) showed groin and umbilicus angiokeratomas.
Three patients showed renal failure with decreased GFR (Table 1) and 19 patients, mainly
those with classical mutations (50% vs 20%), were on enzyme replacement therapy (ERT).
Motor and sensory conduction studies were normal in all patients excluding a peripheral large
nerve fibre involvement even in patients with renal failure.
Gb3 deposits. Abnormal deposits were found in all patients with classical mutations,
whereas all patients with non-classical mutations were negative. FD patients positive for
deposits showed a significant young age compared to negative patients (Table 3). No clear dif-
ference in alpha-GAL activity was found although this value was not available in 13 patients (3
Table 3. Comparison between patients with classical (skin Gb3 positive) and non-classical (Gb3 negative) GLA mutations.
Age Sex Skin innervation αGAL activity
years M:F Leg (EFNs/mm) Thigh (EFNs/mm) %
Pt with positive skin Gb3 39±13 12:20 6±3 9±5 73±80
Pt with negative skin Gb3 48±15* 02:18 9±4** 14±5* 84±38
ENFs = number of unmyelinated fibres per linear millimeter of epidermis
positive vs negative p<0.05*; positive vs negative p<0.01**
https://doi.org/10.1371/journal.pone.0180581.t003
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with classical and 10 with non-classical mutations) making the comparison between these two
FD subgroups difficult.
Skin Gb3 deposits were found in blood vessel walls and endothelial cells, sweat gland
tubules, perineurial, arrector pilorum muscle and dermal cells but never inside the axons (Fig
1). Abnormal deposits were mainly found in males whose skin structures/cells were all
affected, whereas females showed abnormal deposits in all the analysed skin vessels but in 95%
of muscle arrector pilorum cells, 82% of perineurial cells and 47% of sweat gland tubules. Gb3
were not found in dermal cells of females. No differences were found between thigh and leg
regarding the positivity of skin samples and the amount of Gb3 deposits, which were not cor-
related with age, alpha-GAL activity or skin innervation. However, patients with higher Gb3
deposits (100% of skin annexes affected) showed higher although not significant VAS scale (37
±21 vs 28±20; p = 0.3) and autonomic symptoms (67% vs 48%) than patients with lower depos-
its (62±16% of skin annexes affected). Patients on ERT showed higher Gb3 load compared to
patients without ERT (94±10% vs 64±20%, p<0.01) but this finding could be due to a high
number of male patients showing diffuse Gb3 deposits (10 on ERT vs 2 without ERT).
Epidermal innervation. ENFs was decreased in FD patients both in the leg (Fig 2) and
thigh. The decrease was mainly found in males (4±3 and 8±5; leg and thigh respectively) than
in females (8±4 and 13±6), but only the thigh difference was significant (p<0.05). Patients
with classical mutations showed lower ENFs than patients with non-classical mutations both
in the leg and the thigh (Table 3). Furthermore, SFN was more frequently found in the FD
patients with classical mutations (94% vs 70%). Patients on ERT showed lower ENFs both in
the leg (p<0.05) and the thigh (p = 0.06) compared to patients without treatment, but the dif-
ference was likely due to the prevalence of males in the ERT group.
Discussion
The main conclusions of our study were: 1) skin Gb3 deposits are specific to FD patients with
classical GLA mutations; and 2) Gb3 deposits were associated with lower skin innervation but
they were not found inside the axons, suggesting an indirect damage on peripheral small fibre
innervation.
FD diagnosis is difficult due to non-specific onset of symptoms. Abnormal skin Gb3 depos-
its have been studied by complex and expensive techniques involving the use of electron
microscopy[13] although a recent study described a simple immunofluorescence technique to
disclose Gb3 deposits in FD patients[16]. We demonstrated that this technique showed a
promising specificity in identifying FD patients since skin Gb3 deposits were absent in healthy
controls and patients with SFN with a specific cause. In addition, our data demonstrated that
skin Gb3 staining was associated with classical GLA mutations, whereas FD patients with late-
onset FD variants or GLA polymorphisms did not show abnormal Gb3 deposits. These data
could be explained by the association between the GLA classical mutations and a lower alpha-
GAL activity with a damaging effect on the peripheral nervous system, whereas late-onset FD
variants are more often associated with normal alpha-GAL activity, a benign effect on the
peripheral nervous system, and a prevalent cardiac involvement[23–25]. As reported earlier,
our data did not reliably allow us to evaluate the effect of ERT on skin Gb3 deposits because of
a different number of male patients in patients on and without ERT, but also because of a wide
variability of this treatment ranging from 1 to 156 months (Table 1). To address this specific
aim a focused study before and after ERT treatment in age- and sex-matched patients is
required.
SFN is a typical finding in FD[16,20,22] and is responsible for the neuropathic pain com-
plained of by these patients[26]. The mechanism inducing the neuropathic damage is poorly
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understood. Our data showed that SFN characterized patients displaying a classical mutation
but it is more sporadic in patients with non-classical mutations. This finding likely reflects the
higher incidence of pain and autonomic symptoms in patients with classical FD mutations
Fig 1. Skin Gb3 deposits in FD patients with classical GLA mutation. Confocal microscope (x40 in A and B; x60 in C) study of Gb3 in skin
vessels (A, AI and AII), sweat gland tubules (B, BI and BII) and arrector pilorum muscle (C, CI and CII). A) Skin arterioles showed no Gb3 deposits
in the control subject (A). However, these abnormal deposits were abundant in the male FD patient in the wall of the arteriole and its endothelium
(AII) and less evident in the female patient (AI); B) Sweat gland tubules of the control showed no Gb3 deposits (B), which were found in the male
with FD (BII). The female showed nearly absent Gb3 deposits inside the sweat gland tubules (BI); C) Arrector pilorum muscle cells of the control
have no Gb3 deposits (C) but they were found in the male (CII) and less in female FD patient (CI).
https://doi.org/10.1371/journal.pone.0180581.g001
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and skin Gb3 deposits suggesting the involvement of this abnormal deposits in the pathogene-
sis of small fibre damage. Indeed, nerve biopsy in Fabry mice showed abnormal accumulation
of electrodense vesicles, likely Gb3, within a cluster of unmyelinated axons, which can be
responsible of a direct damage to small fibre neurons[17]. By contrast, nerve pathology in FD
patients revealed abundant Gb3 deposits in perineurial, endothelial and smooth muscle cells
but not within peripheral axons suggesting an indirect effect of Gb3 deposits on peripheral
nerve damage by the vasa nervorum obstruction with a subsequent peripheral nerve ischaemia
[18–20]. A possible alternative indirect mechanism could be related to abnormalities in spinal
ganglia induced by Gb3 deposits in cytoplasmic neurons[27,28].
Our data are in line with these conclusions since we did not disclose Gb3 deposits in skin
axons, which were found mainly in the skin vessel walls, sweat gland ducts or arrector pilorum
muscle cells. These findings supported an indirect damage of Gb3 on skin’s small nerve fibres.
In addition, the ENFs lower value of the leg compared to the thigh regardless of a similar Gb3
deposition could suggest a length-dependent dysfunction as the underlying pathogenetic
mechanism affecting small nerve fibres. However, the abnormal expression of ion channels in
peripheral nociceptors could be involved in the neuropathic pain in the mouse model of FD
also contributing to their structural damage, although the mechanism inducing these abnor-
malities is not completely understood[29,30].
Finally, the wide range of intrafamilial phenotypic variability regarding the severity of the
disease but also the affected target-organs in patients with the same GLA mutation [31] should
also be considered analysing the peripheral neuropathy in FD.
Our study has the following limitations: 1) alpha-GAL activity was lacking in several patients
preventing us from establishing a reliable correlation with ERT, skin innervation or Gb3 depos-
its. To this end, an additional study involving a large cohort of patients would be useful; 2) we
analysed few male patients with non-classical mutations. An analysis of these patients will be
helpful in the future to confirm our current data; 3) furthermore, the quantification of Gb3
deposits by an ultrastructural investigation may increase the accuracy of this analysis.
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